This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert Grant, MD, MRCP, MB, ChB; Bernard Naylor, MS, MB, ChB; Harry S. Greenberg, MD; Larry Junck, MD

Arch Neurol. 1994;51(5):457-461.

Abstract
Objective
To critically evaluate the clinical outcome of patients with cytologically proved meningeal carcinomatosis and to identify factors associated with an improved outcome.

Design
A consecutive series of patients was identified from a cytopathology data base. The study period was from 1985 to 1990. Case records and results of radiologic investigations were reviewed; all patients were followed up until their deaths.

Setting
University hospital with a cancer center.

Patients
Thirty-six consecutive patients with cytologically proved meningeal carcinomatosis. Patients with lymphoma or leukemia were excluded.

Interventions
External beam radiation therapy, intrathecal chemotherapy via a ventricular catheter, and intravenous chemotherapy.

Main Outcome Measures
Clinical assessment and survival.

Results
Symptoms improved in 15% of 33 treated patients. Response to treatment had no clear relationship with the age, site of involvement, or tumor type. Median survival for treated patients was only 9 weeks. Patients who received more than five intrareservoir chemotherapy treatments had a median survival of 23 weeks. Median survival for patients with breast carcinoma who received intravenous chemotherapy was 20 weeks, significantly better than that of patients not receiving intravenous chemotherapy.

Conclusions
Survival is poor despite aggressive treatment. Intravenous chemotherapy may improve survival in patients with chemoresponsive primary tumors and deserves further study.

Author Affiliations
From the Departments of Neurology (Drs Grant, Greenberg, and Junck) and Pathology (Mr Naylor), University of Michigan Hospitals, Ann Arbor. Dr Grant is now with the Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases
Brandsma et al.
Neuro Oncol Duke 2006;8:127-136.
ABSTRACT | FULL TEXT  

Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report
POLLAK et al.
J. Neurol. Neurosurg. Psychiatry 2001;70:704-705.
FULL TEXT  

A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors
Glantz et al.
Clin. Cancer Res. 1999;5:3394-3402.
ABSTRACT | FULL TEXT  

Carcinoma Meningitis Secondary to Non-Small Cell Lung Cancer: Combined Modality Therapy
Chamberlain and Kormanik
Arch Neurol 1998;55:506-512.
ABSTRACT | FULL TEXT  

Leptomeningeal Carcinomatosis: Presenting Features and Prognostic Factors
Balm and Hammack
Arch Neurol 1996;53:626-632.
ABSTRACT  

Case 8-1995- A 75-year-old man with multiple cranial-nerve defects and weakness and pain in the extremities
Jones and Edgar
NEJM 1995;332:730-737.
FULL TEXT